Cargando…
Early-phase drug discovery of β-III-spectrin actin-binding modulators for treatment of spinocerebellar ataxia type 5
β-III-Spectrin is a key cytoskeletal protein that localizes to the soma and dendrites of cerebellar Purkinje cells and is required for dendritic arborization and signaling. A spinocerebellar ataxia type 5 L253P mutation in the cytoskeletal protein β-III-spectrin causes high-affinity actin binding. P...
Autores principales: | Guhathakurta, Piyali, Rebbeck, Robyn T., Denha, Sarah A., Keller, Amanda R., Carter, Anna L., Atang, Alexandra E., Svensson, Bengt, Thomas, David D., Hays, Thomas S., Avery, Adam W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978034/ https://www.ncbi.nlm.nih.gov/pubmed/36731793 http://dx.doi.org/10.1016/j.jbc.2023.102956 |
Ejemplares similares
-
Novel drug discovery platform for spinocerebellar ataxia, using fluorescence technology targeting β-III-spectrin
por: Rebbeck, Robyn T., et al.
Publicado: (2020) -
Increased actin binding is a shared molecular consequence of numerous spinocerebellar ataxia mutations in β-III-spectrin
por: Atang, Alexandra E., et al.
Publicado: (2023) -
β-III-spectrin N-terminus is required for high-affinity actin binding and SCA5 neurotoxicity
por: Denha, Sarah A., et al.
Publicado: (2022) -
Increased Actin Binding Is a Shared Molecular Consequence of Numerous SCA5 Mutations in β-III-Spectrin
por: Atang, Alexandra E., et al.
Publicado: (2023) -
A human β-III-spectrin spinocerebellar ataxia type 5 mutation causes high-affinity F-actin binding
por: Avery, Adam W., et al.
Publicado: (2016)